Breast Care A-Z · Condition · IBC

Inflammatory breast cancer

also: IBC, inflammatory carcinoma of the breast

Inflammatory breast cancer is a rare, aggressive breast cancer that makes the breast look red, swollen, and warm — often without a distinct lump — because cancer cells block the skin's lymph channels. You may have been told IBC is being considered, or be reading because a red, swollen breast is not settling with treatment for an infection.

Quick answers

My GP gave me antibiotics for a red, swollen breast — should I be worried?

Most cases of red, swollen breast are infection and respond to antibiotics. The question to come back on is whether the redness and swelling are settling within 48–72 hours. If they are not, return to your GP for review and request specialist assessment — that is the pattern that warrants urgent imaging and biopsy.

Is inflammatory breast cancer always rapidly fatal?

No. Outcomes have improved significantly with modern multimodal treatment over the past two decades. IBC remains less favourable than typical breast cancer at the same stage, but many patients do well with full treatment, particularly for HER2-positive IBC where targeted therapy has changed the picture.

Why doesn't IBC usually have a discrete lump?

IBC grows in a diffuse pattern that infiltrates through the breast tissue and into the dermal lymphatic vessels of the skin, rather than forming a defined mass. The "inflammatory" appearance comes from the lymphatic blockage and tissue oedema this causes — it is not infection.

ONCOLOGY · RARE BREAST CANCERS PLATE LV inflammatory breast cancer IBC · T4d breast carcinoma a rare but rapidly progressive locally advanced breast cancer without a palpable mass FIG 01 IBC Clinical Signs — Breast Surface Diagram (inverted) Dermal lymphatics tumour emboli i — diffuse erythema (>1/3 of breast skin) ii — peau d'orange (dermal oedema from lymphatic blockage) iii — dermal lymphatic tumour emboli iv — rapid onset (weeks to months per AJCC T4d) v — no discrete palpable mass (may be absent) Diagnostic criteria (AJCC T4d) • Rapid onset breast enlargement (weeks) • Erythema of >1/3 of breast skin • Peau d'orange (dimpled / orange-peel texture) • Often no palpable discrete mass • Pathological confirmation of invasive carcinoma required • Must exclude other causes (mastitis, abscess) Diagnostic Criteria (AJCC T4d) • Rapid onset breast enlargement • Erythema >1/3 of breast • Peau d'orange present • Often no palpable mass • Pathological confirmation required • Exclude mastitis / abscess first IBC vs Mastitis Mastitis Fever, focal, responds to abx in 1 wk IBC No fever, diffuse, no abx response No response? Urgent biopsy within 1 week FIG 02 IBC vs Non-IBC Locally Advanced Breast Cancer Parameter IBC Non-IBC LABC Presentation Skin changes, rapid onset Mass ± skin involvement T stage T4d T4a / b / c Palpable mass Often absent Usually present Onset Weeks Weeks to months Mammogram Skin thickening, diffuse density Mass lesion Biopsy Skin punch biopsy for emboli Core biopsy of mass Prognosis Worse (5-yr ~40%) Better Treatment Neoadjuvant chemo first Variable Surgery Mastectomy after chemo (BCS not advised) BCS possible Sentinel node Usually not performed Sometimes appropriate FIG 03 Clinical Mimics of IBC — Differential Diagnosis Condition Distinguishing Features Differentiator Lactational mastitis Fever, focal, <6 wks post-partum Resolves with antibiotics Periductal mastitis Periareolar, non-lactating Responds to abx / surgery Breast abscess Fluctuant, focal, systemic upset Drainage + antibiotics resolve LABC non-IBC Mass palpable, slower onset Imaging + biopsy Radiation dermatitis History of prior RT Clinical history Angiosarcoma Skin lesion, post-RT Biopsy + imaging Contact dermatitis Bilateral, clear cause History Paget's disease Nipple only, chronic Nipple biopsy Recurrent cancer Prior breast cancer history History + biopsy FIG 04 Clinical Pathway — Inflammatory Breast Cancer 1 Urgent presentation / A&E or GP 2 2WW urgent breast clinic referral 3 Punch biopsy (skin) + core biopsy 4 Staging (CT + bone scan) 5 Neoadjuvant chemotherapy (± anti-HER2) 6 Mastectomy + axillary clearance + adjuvant RT FIG 05 IBC Subtypes & Treatment Modalities Classic IBC (T4d) HER2-positive IBC Triple-negative IBC Neoadjuvant chemotherapy Post-chemo mastectomy Adjuvant radiotherapy (whole chest) FIG 06 Key Statistics ~1–5% of all breast cancers [1] 5-yr survival ~40% vs ~86% non-IBC [2] Median diagnosis age 52 years [3] pCR rate ~30–40% with neoadjuvant chemo [4] FIG 07 References 1. Dawood S et al. Epidemiology of IBC. Ann Oncol 2011 2. Rueth NM et al. IBC outcomes. J Natl Cancer Inst 2011 3. SEER database. IBC statistics 2023 4. Bertucci F et al. IBC treatment outcomes. Oncologist 2010 5. NICE NG101. Locally advanced breast cancer 2023 Clinically authored by Dr Fiona Tsang-Wright , FRCS (Gen Surg) GMC 4549831 · ORCID 0000-0003-4801-026X
Visual Reference · Inflammatory breast cancer
Open full size ↗
Definition
Inflammatory breast cancer is a rare and aggressive form of breast cancer that presents with rapid-onset redness, swelling, and skin thickening of the breast — symptoms that often mimic infection — rather than as a discrete lump.

Common questions The questions patients ask first

My GP gave me antibiotics for a red, swollen breast — should I be worried?
Most cases of red, swollen breast are infection and respond to antibiotics. The question to come back on is whether the redness and swelling are settling within 48–72 hours. If they are not, return to your GP for review and request specialist assessment — that is the pattern that warrants urgent imaging and biopsy.
Is inflammatory breast cancer always rapidly fatal?
No. Outcomes have improved significantly with modern multimodal treatment over the past two decades. IBC remains less favourable than typical breast cancer at the same stage, but many patients do well with full treatment, particularly for HER2-positive IBC where targeted therapy has changed the picture.
Why doesn't IBC usually have a discrete lump?
IBC grows in a diffuse pattern that infiltrates through the breast tissue and into the dermal lymphatic vessels of the skin, rather than forming a defined mass. The "inflammatory" appearance comes from the lymphatic blockage and tissue oedema this causes — it is not infection.
Can IBC happen in men?
Yes, very rarely. Male IBC is treated using the same principles as female IBC and is usually picked up because the changes are visible.

Inflammatory breast cancer is a rare and aggressive form of breast cancer that presents with rapid-onset redness, swelling, and skin thickening of the breast — symptoms that often mimic infection — rather than as a discrete lump.

IBC accounts for around 1–5% of breast cancers1 but is one of the most important diagnoses not to miss because it can look like a breast infection. It is faster-growing than typical breast cancer and is treated with a defined sequence: chemotherapy first, then mastectomy with axillary clearance, then radiotherapy, with adjuvant therapy based on receptor status. Outcomes have improved with this multimodal approach but remain less favourable than for typical invasive breast cancer at the same stage.

Orientation Why you might be reading about this

You may have been told that IBC is being considered, or you are reading because you have a red, swollen breast that is not responding as expected to treatment for an infection. The reason this entry exists is that IBC is the diagnosis that must not be missed when a breast looks inflamed but does not settle on antibiotics — and recognising the pattern is the most useful thing this page can do.

Related terms: Invasive ductal carcinoma · Invasive lobular carcinoma · Mastectomy · Core biopsy

Presentation How IBC presents

Inflammatory breast cancer is named for how it looks, not how it grows microscopically. Unlike most breast cancers, which present as a discrete lump, IBC presents with a constellation of skin and breast changes:

  • Rapid-onset redness of the breast — sometimes covering more than a third of the breast surface — typically over weeks rather than months.
  • Swelling and a feeling of heaviness of the affected breast, often noticeably larger than the other side.
  • Skin thickening with a dimpled, pitted appearance — sometimes called peau d’orange (French for “orange peel skin”), reflecting the appearance of the deeply tethered skin pores against thickened tissue.
  • Warmth and tenderness of the affected breast.
  • No discrete lump in many cases — examination may feel diffuse thickening rather than a defined mass.
  • Inverted or flattened nipple in some cases.
  • Enlarged lymph nodes under the arm.

The pattern develops quickly — typically over 3 to 6 weeks1 — distinguishing it from the slow growth of most breast cancers. The presentation can be mistaken for mastitis or a breast abscess, particularly outside of the breastfeeding context.

Why it matters Why the “infection that doesn’t settle” pattern matters

Most cases of red, swollen breast in clinical practice are infection (mastitis or abscess). The standard first step is antibiotics3, with the expectation of improvement within 48–72 hours.

A red, swollen breast that does not settle within 48–72 hours of appropriate antibiotics is a red flag for IBC1. At that point, the pathway changes: prompt imaging (mammogram, ultrasound, often MRI) and biopsy of the skin and underlying breast tissue are arranged, even when infection seems the more likely diagnosis. This caution is built into UK breast practice precisely because IBC can look like infection.

For more on the differential, see mastitis and breast abscess.

Diagnosis Diagnosis

The diagnostic pathway for suspected IBC includes:

  • Clinical examination — documenting the extent of the skin changes and breast asymmetry.
  • Mammogram and ultrasound — looking for an underlying mass, skin thickening, and enlarged lymph nodes. Sometimes the imaging is more diffuse than for typical breast cancer, with no discrete mass.
  • Breast MRI — often added because it shows the extent of disease in the breast and skin more clearly.
  • Core biopsy — of any underlying mass or thickened area, plus a skin punch biopsy to look for cancer cells in the dermal lymphatic vessels (the microscopic feature that distinguishes IBC).
  • Staging investigations — usually CT chest/abdomen/pelvis and a bone scan, because IBC has a higher chance of metastatic spread at presentation than typical breast cancer.

The diagnosis of IBC is based on the clinical pattern plus biopsy confirmation of cancer. Cancer cells in dermal lymphatic vessels are characteristic but not always seen on biopsy; the clinical picture remains the most important factor.

Treatment Treatment

IBC is treated as stage III breast cancer at minimum and follows a defined multimodal sequence:

  1. Neoadjuvant chemotherapy — chemotherapy before surgery, given over several months. For HER2-positive IBC, targeted antibody therapy (trastuzumab plus pertuzumab) is added to chemotherapy.
  2. Mastectomy with axillary clearance — IBC is not usually a candidate for breast-conserving surgery because of the diffuse skin and breast involvement. Sentinel lymph node biopsy is generally not used; full axillary clearance is the standard.
  3. Radiotherapy — to the chest wall and regional lymph nodes after surgery.
  4. Adjuvant systemic therapy — hormone therapy for ER-positive IBC, continued targeted therapy for HER2-positive IBC, and (in selected cases) further chemotherapy or newer agents such as PARP inhibitors for BRCA-positive triple-negative IBC.

Reconstruction is usually delayed — performed months or years after the radiotherapy course is complete, rather than at the time of mastectomy — because immediate reconstruction is more vulnerable to radiotherapy effects in the IBC setting.

The whole treatment pathway typically runs over 9–12 months from diagnosis1.

Outlook Outlook

IBC is more aggressive than typical breast cancer and outcomes are less favourable when matched for stage. With modern multimodal treatment, however, outcomes have improved meaningfully — particularly for HER2-positive IBC, which has benefited from targeted therapy. Specific prognostic figures depend on the receptor status, response to neoadjuvant therapy, and the presence or absence of distant spread at diagnosis.

At consultation What to discuss with your surgeon

If IBC is being considered:

  • The diagnostic pathway — imaging, biopsy of breast tissue and skin, staging investigations.
  • The treatment sequence — chemotherapy first, then surgery, then radiotherapy.
  • Why mastectomy rather than lumpectomy — IBC is not generally a candidate for breast-conserving surgery.
  • Reconstruction planning — delayed rather than immediate, because of radiotherapy.
  • Genetic testing — IBC sometimes prompts genetic testing, particularly if triple-negative or in younger patients.

Resources Further reading

Sources & guidance

Every figure on this page is anchored to a published source. Tap a number in the text or below to jump to the reference.

  1. review Robertson FM, Bondy M, Yang W, et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA: A Cancer Journal for Clinicians. 2010 ;60(6):351-375 doi:10.3322/caac.20082 Cited for: Inflammatory breast cancer prevalence (1-5%), clinical presentation, neoadjuvant chemotherapy standard.
  2. guidance National Institute for Health and Care Excellence (NICE). Suspected cancer: recognition and referral. NICE guideline NG12. London: NICE. 2023 https://www.nice.org.uk/guidance/ng12 Cited for: Two-week-wait referral criteria and triple-assessment standard for suspected breast cancer.